integrated the genomic data and clinical outcomes in 179 patients with advanced EGFR-mutated NSCLC and found that EGFR-mutant patients harboring concomitant TP53 mutation were significantly associated with a poorer clinical prognosis (OS: 21 vs. 40 months, P = 0.05) after treated with 1st generation EGFR-TKI. This evidence concerns the gene EGFR and non-small cell lung carcinoma.